Active, Not Recruiting
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia - CA209-870
Updated: 3 June, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Advanced metastatic stage IIIB/IV NSCLC (Nonsquamous and squamous) - 1 to 2 prior systemic therapies - Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 1 - Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) - Prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to starting study treatment Exclusion Criteria: - Women with a positive pregnancy test at enrollment or prior to administration of study medication - Participants with active central nervous system metastases - Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first dose of study drug - Participants with previous malignancies are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required or anticipated to be required during the study period - Participants with carcinomatous meningitis Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
